Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three

ISAAC Phase Three Study Group

Research output: Contribution to journalArticle

378 Citations (Scopus)

Abstract

Background: In 1999, The International Study of Asthma and Allergies in Childhood (ISAAC) Phase One reported the prevalence of eczema symptoms in 715,033 children from 154 centers in 56 countries by using standardized epidemiologic tools. Objective: To update the world map of eczema prevalence after 5 to 10 years (ISAAC Phase Three) and include additional data from over 100 new centers. Methods: Cross-sectional surveys using the ISAAC questionnaire on eczema symptoms were completed by adolescents 13 to 14 years old and by parents of children 6 to 7 years old. Current eczema was defined as an itchy flexural rash in the past 12 months and was considered severe eczema if associated with 1 or more nights per week of sleep disturbance. Results: For the age group 6 to 7 years, data on 385,853 participants from 143 centers in 60 countries showed that the prevalence of current eczema ranged from 0.9% in India to 22.5% in Ecuador, with new data showing high values in Asia and Latin America. For the age group 13 to 14 years, data on 663,256 participants from 230 centers in 96 countries showed prevalence values ranging from 0.2% in China to 24.6% in Columbia with the highest values in Africa and Latin America. Current eczema was lower for boys than girls (odds ratio, 0.94 and 0.72 at ages 6 to 7 years and 13 to 14 years, respectively). Conclusion:ISAAC Phase Three provides comprehensive global data on the prevalence of eczema symptoms that is essential for public health planning. New data reveal that eczema is a disease of developing as well as developed countries.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology
Volume124
Issue number6
DOIs
StatePublished - Dec 1 2009

Fingerprint

Eczema
Hypersensitivity
Asthma
Latin America
Age Groups
Ecuador
Health Planning
Exanthema
Developed Countries
Developing Countries
India
China
Sleep
Public Health
Cross-Sectional Studies
Parents
Odds Ratio

Keywords

  • Eczema
  • ISAAC
  • children
  • global
  • prevalence
  • sex

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. / ISAAC Phase Three Study Group.

In: Journal of Allergy and Clinical Immunology, Vol. 124, No. 6, 01.12.2009.

Research output: Contribution to journalArticle

@article{bfdf630833464f62a1ca2f3b1ce5e220,
title = "Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three",
abstract = "Background: In 1999, The International Study of Asthma and Allergies in Childhood (ISAAC) Phase One reported the prevalence of eczema symptoms in 715,033 children from 154 centers in 56 countries by using standardized epidemiologic tools. Objective: To update the world map of eczema prevalence after 5 to 10 years (ISAAC Phase Three) and include additional data from over 100 new centers. Methods: Cross-sectional surveys using the ISAAC questionnaire on eczema symptoms were completed by adolescents 13 to 14 years old and by parents of children 6 to 7 years old. Current eczema was defined as an itchy flexural rash in the past 12 months and was considered severe eczema if associated with 1 or more nights per week of sleep disturbance. Results: For the age group 6 to 7 years, data on 385,853 participants from 143 centers in 60 countries showed that the prevalence of current eczema ranged from 0.9{\%} in India to 22.5{\%} in Ecuador, with new data showing high values in Asia and Latin America. For the age group 13 to 14 years, data on 663,256 participants from 230 centers in 96 countries showed prevalence values ranging from 0.2{\%} in China to 24.6{\%} in Columbia with the highest values in Africa and Latin America. Current eczema was lower for boys than girls (odds ratio, 0.94 and 0.72 at ages 6 to 7 years and 13 to 14 years, respectively). Conclusion:ISAAC Phase Three provides comprehensive global data on the prevalence of eczema symptoms that is essential for public health planning. New data reveal that eczema is a disease of developing as well as developed countries.",
keywords = "Eczema, ISAAC, children, global, prevalence, sex",
author = "{ISAAC Phase Three Study Group} and Odhiambo, {Joseph A.} and Williams, {Hywel C.} and Clayton, {Tadd O.} and Robertson, {Colin F.} and {Innes Asher}, M. and N. A{\~A}¯t-Khaled and Anderson, {H. R.} and Asher, {M. I.} and R. Beasley and {Bj {\~A}– Rkst{\~A}{\circledC}n}, B. and B. Brunekreef and J. Crane and P. Ellwood and C. Flohr and S. Foliaki and F. Forastiere and L. Garc{\~A}­a-Marcos and U. Keil and Lai, {C. K.W.} and J. Mallol and Mitchell, {E. A.} and S. Montefort and J. Odhiambo and N. Pearce and Stewart, {A. W.} and D. Strachan and {von Mutius}, E. and Weiland, {S. K.} and G. Weinmayr and H. Williams and G. Wong and A. Priftanji and B. Benhabyl{\~A}¨s and Baena-Cagnani, {C. E.} and Crisci, {C. D.} and M. G{\~A}³mez and Zabert, {G. E.} and G. Haidinger and Howitt, {M. E.} and J. Weyler and R. Pinto-Vargas and Bernhardt, {C. D.S.D.} and Borges, {W. G.} and Camargos, {P. A.M.} and Cardoso, {M. D.S.} and Cunha, {A. J.L.A.} and Fischer, {G. B.} and Motta, {J. M.} and Neto, {A. P.} and Monteil, {Michele Anne}",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/j.jaci.2009.10.009",
language = "English (US)",
volume = "124",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three

AU - ISAAC Phase Three Study Group

AU - Odhiambo, Joseph A.

AU - Williams, Hywel C.

AU - Clayton, Tadd O.

AU - Robertson, Colin F.

AU - Innes Asher, M.

AU - Aït-Khaled, N.

AU - Anderson, H. R.

AU - Asher, M. I.

AU - Beasley, R.

AU - Bj Ö Rkstén, B.

AU - Brunekreef, B.

AU - Crane, J.

AU - Ellwood, P.

AU - Flohr, C.

AU - Foliaki, S.

AU - Forastiere, F.

AU - García-Marcos, L.

AU - Keil, U.

AU - Lai, C. K.W.

AU - Mallol, J.

AU - Mitchell, E. A.

AU - Montefort, S.

AU - Odhiambo, J.

AU - Pearce, N.

AU - Stewart, A. W.

AU - Strachan, D.

AU - von Mutius, E.

AU - Weiland, S. K.

AU - Weinmayr, G.

AU - Williams, H.

AU - Wong, G.

AU - Priftanji, A.

AU - Benhabylès, B.

AU - Baena-Cagnani, C. E.

AU - Crisci, C. D.

AU - Gómez, M.

AU - Zabert, G. E.

AU - Haidinger, G.

AU - Howitt, M. E.

AU - Weyler, J.

AU - Pinto-Vargas, R.

AU - Bernhardt, C. D.S.D.

AU - Borges, W. G.

AU - Camargos, P. A.M.

AU - Cardoso, M. D.S.

AU - Cunha, A. J.L.A.

AU - Fischer, G. B.

AU - Motta, J. M.

AU - Neto, A. P.

AU - Monteil, Michele Anne

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Background: In 1999, The International Study of Asthma and Allergies in Childhood (ISAAC) Phase One reported the prevalence of eczema symptoms in 715,033 children from 154 centers in 56 countries by using standardized epidemiologic tools. Objective: To update the world map of eczema prevalence after 5 to 10 years (ISAAC Phase Three) and include additional data from over 100 new centers. Methods: Cross-sectional surveys using the ISAAC questionnaire on eczema symptoms were completed by adolescents 13 to 14 years old and by parents of children 6 to 7 years old. Current eczema was defined as an itchy flexural rash in the past 12 months and was considered severe eczema if associated with 1 or more nights per week of sleep disturbance. Results: For the age group 6 to 7 years, data on 385,853 participants from 143 centers in 60 countries showed that the prevalence of current eczema ranged from 0.9% in India to 22.5% in Ecuador, with new data showing high values in Asia and Latin America. For the age group 13 to 14 years, data on 663,256 participants from 230 centers in 96 countries showed prevalence values ranging from 0.2% in China to 24.6% in Columbia with the highest values in Africa and Latin America. Current eczema was lower for boys than girls (odds ratio, 0.94 and 0.72 at ages 6 to 7 years and 13 to 14 years, respectively). Conclusion:ISAAC Phase Three provides comprehensive global data on the prevalence of eczema symptoms that is essential for public health planning. New data reveal that eczema is a disease of developing as well as developed countries.

AB - Background: In 1999, The International Study of Asthma and Allergies in Childhood (ISAAC) Phase One reported the prevalence of eczema symptoms in 715,033 children from 154 centers in 56 countries by using standardized epidemiologic tools. Objective: To update the world map of eczema prevalence after 5 to 10 years (ISAAC Phase Three) and include additional data from over 100 new centers. Methods: Cross-sectional surveys using the ISAAC questionnaire on eczema symptoms were completed by adolescents 13 to 14 years old and by parents of children 6 to 7 years old. Current eczema was defined as an itchy flexural rash in the past 12 months and was considered severe eczema if associated with 1 or more nights per week of sleep disturbance. Results: For the age group 6 to 7 years, data on 385,853 participants from 143 centers in 60 countries showed that the prevalence of current eczema ranged from 0.9% in India to 22.5% in Ecuador, with new data showing high values in Asia and Latin America. For the age group 13 to 14 years, data on 663,256 participants from 230 centers in 96 countries showed prevalence values ranging from 0.2% in China to 24.6% in Columbia with the highest values in Africa and Latin America. Current eczema was lower for boys than girls (odds ratio, 0.94 and 0.72 at ages 6 to 7 years and 13 to 14 years, respectively). Conclusion:ISAAC Phase Three provides comprehensive global data on the prevalence of eczema symptoms that is essential for public health planning. New data reveal that eczema is a disease of developing as well as developed countries.

KW - Eczema

KW - ISAAC

KW - children

KW - global

KW - prevalence

KW - sex

UR - http://www.scopus.com/inward/record.url?scp=71149109926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71149109926&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2009.10.009

DO - 10.1016/j.jaci.2009.10.009

M3 - Article

C2 - 20004783

AN - SCOPUS:71149109926

VL - 124

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 6

ER -